This care card's answer
The national list is what matters here.
The Food and Drug Administration (FDA), the U.S. medicine regulator, keeps the national shortage list used in the compounding rules.
On September 26, 2026, that shortage list had no entries for either semaglutide injections or tirzepatide injections.
Ask which rule supports the preparation.
Ordinary compounding pharmacies face limits on making routine or large numbers of copies of medicines already available to buy.
A prescriber may find that altering the medicine meets an individual patient's medical need that the available medicine cannot meet. A lower price alone does not qualify.
For example, an approved tablet may not meet a patient's need if they cannot swallow it or are allergic to a dye in it.
Ask the prescriber to explain the proposed change to your medicine and how it addresses your health needs.
Ask for the reason that applies to your preparation. An old headline about shortages does not answer that question.
Keep the answer specific to the medicine.
Depending on the product, liraglutide (Victoza, Saxenda) treats type 2 diabetes or is used to help with weight loss. It was still on FDA's shortage list on September 26, 2026.
Do not carry the answer for one ingredient over to another.
Take this to the conversation
Does this rely on a current national shortage or a documented change for my own medical need?
Ask for the answer in plain words. Keep it with your visit notes.
Notes behind this answer
- FDA: supply changes and compounding policy
Explains how the end of shortages affects copies.
- FDA: the role of the shortage list
Covers the national listing used by compounders.
- FDA: liraglutide shortage record
This ingredient has a different record from semaglutide and tirzepatide.